Search

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

A Few Ways We Support US Livestock | Boehringer Ingelheim US

Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

Evolving the Unwearable Collection

Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

Vikas joined from hospital sector

Are you considering moving into pharmaceuticals for the first time? Vikas made the leap and has never looked back.

History of our Logo | Corporate Profile | Boehringer Ingelheim US

The logo used by Boehringer Ingelheim today is a stylized depiction of the central section of the imperial palace of Charlemagne.

Novel antibody shows potential to transform treatment of rare form of psoriasis

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

How Simulation is Changing the Game in Biotherapeutic Drug Development

Chronic Kidney Disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Volunteering to Strengthen the Human-Animal Bond

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US

Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.

Search

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

200 employees make a difference with record-breaking volunteer efforts

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

A Few Ways We Support US Livestock | Boehringer Ingelheim US

FDA approves additional formulation of biosimilar

Flying animals to safety with Greater Good Charities

Evolving the Unwearable Collection

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

Innovation from within

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

Vikas joined from hospital sector

History of our Logo | Corporate Profile | Boehringer Ingelheim US

Novel antibody shows potential to transform treatment of rare form of psoriasis

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

How Simulation is Changing the Game in Biotherapeutic Drug Development

Chronic Kidney Disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Volunteering to Strengthen the Human-Animal Bond

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

200 employees make a difference with record-breaking volunteer efforts

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

A Few Ways We Support US Livestock | Boehringer Ingelheim US

FDA approves additional formulation of biosimilar

Flying animals to safety with Greater Good Charities

Evolving the Unwearable Collection

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

Innovation from within

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

Vikas joined from hospital sector

History of our Logo | Corporate Profile | Boehringer Ingelheim US

Novel antibody shows potential to transform treatment of rare form of psoriasis

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

How Simulation is Changing the Game in Biotherapeutic Drug Development

Chronic Kidney Disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Volunteering to Strengthen the Human-Animal Bond

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US